Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Gronchi, Alessandro; Miah, Aisha; Tos, Angelo Paolo Dei; Abecassis, N.; Bajpai, Jyoti; Bauer, Sebastian; Biagini, R.; Bielack, Stefan; Blay, Jean‐Yves; Bolle, Stéphanie; Bonvalot, Sylvie; Boukovinas, I.; Bovée, Judith; Boye, Kjetil; Brennan, Bernadette; Brodowicz, Thomas; Buonadonna, Angela; Álava, Enrique de; Muro, Xavier García del; Dufresne, Armelle; Eriksson, Mikael; Fagioli, Franca; Феденко, А. А.; Ferraresi, Virginia; Ferrari, Andrea; Frezza, Anna Maria; Gasperoni, Silvia; Gelderblom, Hans; Gouin, F.; Grignani, Giovanni; Haas, Rick L.; Hassan, A B; Hecker‐Nolting, Stefanie; Hindi, Nadia; Hohenberger, Peter; Joensuu, Heikki; Jones, Robin L.; Jungels, Christiane; Jutte, Paul C.; Kager, Leo; Kasper, Bernd; Kawai, Akira; Kopečková, Kateřina; Krákorová, Dagmar Adámková; Cesne, Axel Le; Grange, Franel le; Legius, Eric; Leithner, Andreas; López‐Pousa, Antonio; Martin‐Broto, Javier; Merimsky, Ofer; Messiou, Christina; Mir, Olivier; Montemurro, Michael; Morland, Bruce; Morosi, Carlo; Palmerini, Emanuela; Pantaleo, Maria Abbondanza; Piana, Raimondo; Piperno‐Neumann, Sophie; Reichardt, Peter; Rutkowski, Piotr; Safwat, Akmal; Sangalli, Claudia; Sbaraglia, Marta; Scheipl, Susanne; Schöffski, Patrick; Sleijfer, Stefan; Strauß, D.; Strauss, Sandra J.; Hall, Kirsten Sundby; Trama, Annalisa; Unk, Mojca; Sande, Michiel A.J. van de; Graaf, Winette T.A. van der; Houdt, Winan J. van; Frébourg, Thierry; Casali, Paolo G.; Stacchiotti, Silvia

doi:10.1016/j.annonc.2021.07.006

Cited by 418 publications

(187 citation statements)

References 99 publications

Supporting

Mentioning

186

Contrasting

Order By: Relevance

“…This multiparametric analysis showed that both SUVmax and SUVpeak provide prognostic value, next to the two strongest predictive clinical characteristics. Furthermore, the [ 18 F]FDG-PET scans are often performed in standard clinical practice for staging of disease, and therefore, the features can be determined without extra costs and distress for the patients [ 7 ]. There are some limitations to this study.…”

Section: Discussionmentioning

confidence: 99%

“…Generally, therapies can consist of combinations of surgery, radiotherapy, and systemic treatment. Personalized decision making is important in designing treatment strategies, and a multitude of parameters is used for this purpose [ 7 ]. Prognostic factors play an important role among these parameters, and several studies have identified a group of characteristics that is associated with prognosis in these patients [ 4 , 5 , 6 , 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

et al. 2021

View full text Add to dashboard Cite

Background: Prognostic biomarkers are pivotal for adequate treatment decision making. The objective of this study was to determine the added prognostic value of quantitative [18F]FDG-PET features in patients with metastases from soft tissue sarcoma (STS). Methods: Patients with metastases from STS, detected by (re)staging [18F]FDG-PET/CT at Leiden University Medical Centre, were retrospectively included. Clinical and histopathological patient characteristics and [18F]FDG-PET features (SUVmax, SUVpeak, SUVmean, total lesion glycolysis, and metabolic tumor volume) were analyzed as prognostic factors for overall survival using a Cox proportional hazards model and Kaplan–Meier methods. Results: A total of 31 patients were included. SUVmax and SUVpeak were significantly predictive for overall survival (OS) in a univariate analysis (p = 0.004 and p = 0.006, respectively). Hazard ratios (HRs) were 1.16 per unit increase for SUVmax and 1.20 per unit for SUVpeak. SUVmax and SUVpeak remained significant predictors for overall survival after correction for the two strongest predictive clinical characteristics (number of lesions and performance status) in a multivariate analysis (p = 0.02 for both). Median SUVmax and SUVpeak were 5.7 and 4.9 g/mL, respectively. The estimated mean overall survival in patients with SUVmax > 5.7 g/mL was 14 months; otherwise, it was 39 months (p < 0.001). For patients with SUVpeak > 4.9 g/mL, the estimated mean overall survival was 18 months; otherwise, it was 33 months (p = 0.04). Conclusions: In this study, SUVmax and SUVpeak were independent prognostic factors for overall survival in patients with metastases from STS. These results warrant further investigation of metabolic imaging with [18F]FDG-PET/CT in patients with metastatic STS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The optimal management of patients with metastatic MPNST is an important field of research. Palliative systemic therapy is the standard treatment in widespread metastatic disease [8]. However, metastasectomy is recommended in isolated resectable lung metastases (with a DFI ≥ 1 year), if complete excision of the lesions is feasible [8].…”

Section: Treatment Of Metastatic Mpnstmentioning

confidence: 99%

“…Palliative systemic therapy is the standard treatment in widespread metastatic disease [8]. However, metastasectomy is recommended in isolated resectable lung metastases (with a DFI ≥ 1 year), if complete excision of the lesions is feasible [8]. Especially in the metastatic setting, the anticipated side effects of these treatment modalities should be well balanced with the expected benefits.…”

Section: Treatment Of Metastatic Mpnstmentioning

confidence: 99%

See 1 more Smart Citation

The Association of Metastasis Pattern and Management of Metastatic Disease with Oncological Outcomes in Patients with Malignant Peripheral Nerve Sheath Tumors: A Multicenter Cohort Study

Acem

Martin

Houdt

et al. 2021

Cancers

View full text Add to dashboard Cite

Purpose: This multicenter cohort study aimed to identify clinicopathologic and treatment-related factors associated with the development of distant metastasis (DM) and with overall survival (OS) after DM diagnosis in patients with malignant peripheral nerve sheath tumors (MPNST). Methods: All patients diagnosed with primary MPNST from 1988 to 2019 who were surgically treated for the primary tumor were included. Multivariable Cox regression analyses were performed to identify factors associated with DM and OS after DM diagnosis. Results: A total of 383 patients were included in this analysis, of which 150 developed metastatic disease. No differences in clinicopathologic characteristics and clinical outcome were found between patients with synchronous and metachronous DM. Neurofibromatosis type 1 (NF1), high grade, tumor size, triton and R2 resections were independent risk factors for the development of DM. NF1 and more than two metastasis sites were independently associated with worse OS after DM diagnosis. Metastasectomy, chemotherapy and the metastatic site category ‘other’ were associated with prolonged survival after DM diagnosis. Conclusion: This analysis provides important insights into clinicopathologic and treatment factors associated with outcomes in metastatic MPNST. Moreover, NF1-status is associated with a higher risk of DM; it is also independently associated with worse survival in metastatic MPNST.

show abstract

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma

et al. 2022

View full text Add to dashboard Cite

ImportanceTreatment options for patients with unresectable and/or metastatic dedifferentiated liposarcoma (DDLPS) are limited. New drugs are required.ObjectiveTo assess whether cabazitaxel demonstrated sufficient antitumor activity in patients with metastatic or inoperable locally advanced DDLPS to justify further investigation in a phase 3 setting.Design, Setting, and ParticipantsThis international multicenter, open-label single-arm phase 2 trial was conducted at 10 institutions in 4 European countries from March 2015 to March 2019. Eligible patients had to have metastatic or locally advanced histologically proven DDLPS with evidence of disease progression within the past 6 months and had to have received no more than 1 previous line of chemotherapy.InterventionsAfter mandatory central review of tumor blocks, if the DDLPS diagnosis was confirmed, patients started treatment within 72 hours after registration. Cabazitaxel was administered at a dose of 25 mg/m2 IV infusion over 1 hour every 21 days until intolerance, progression, or withdrawal of consent.Main Outcomes and MeasuresThe primary end point was progression-free survival (PFS) rate at 12 weeks per RECIST 1.1. Based on a Simon 2-stage design, at least 4 of 17 (stage 1) and 11 of 37 (stage 2) eligible and evaluable patients who were progression free at 12 weeks were needed. The final analysis report was completed on November 17, 2021.ResultsForty patients were registered, with 2 patients being ineligible. The number of cycles ranged from 1 to 30, with a median of 5; 26 patients (65%) received at least 4 cycles of cabazitaxel. Progression-free survival at 12 weeks was 55%, achieving the primary study end point. At a median follow-up of 21.6 months, median PFS was 6 months and median OS 21 months. Response rate (RR) was 8% with 1 clinical response (CR) and 2 partial responses (PR). Twenty-three (60.5%) patients had a stable disease (SD). Disease control (PR+SD) was achieved in 26 patients (68%).Conclusions and RelevanceThis nonrandomized phase 2 clinical trial met its primary end point, with 21 of 38 patients (55%) being progression free at 12 weeks. These results suggest important activity of cabazitaxel in patients with metastatic or inoperable locally advanced DDLPS. The drug is worth being further studied in these tumors in a phase 3 setting.

show abstract

Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆

Cited by 418 publications

References 99 publications

Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

Prognostic Value of Quantitative [18F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

The Association of Metastasis Pattern and Management of Metastatic Disease with Oncological Outcomes in Patients with Malignant Peripheral Nerve Sheath Tumors: A Multicenter Cohort Study

Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma

Contact Info

Product

Resources

About